SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer

Lin, Lifeng; Shi, Kaixuan; Zhou, Shaoqiang; Cai, Mei-Chun; Zhang, Caiyan; Sun, Yunheng; Zang, Jingyu; Tan, Li; Zhuang, Guanglei; Zang, Rongyu

doi:10.3802/jgo.2021.32.s1.o17

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2a, Supplementary Table 1). Cells in state 1 express gene module A, which includes ovarian cancer lineage-defining transcription factors such as SOX17 and PAX8 (18)(19)(20) and the WT1 prognostic marker (20), as well as epithelial (KRT8, DSP) and interferon response markers (IFI6, IFI27), indicating that untreated or lower-dose adapted cells retained their ancestral lineage identity. Cells in state 3 express module B, which has a hybrid expression of epithelial (KRT8, KRT18) and mesenchymal markers (FN1).…”

Section: Assembly Of Gene Module Expression Accompanies Drug-induced ...mentioning

confidence: 99%

Drug-induced adaptation along a resistance continuum in cancer cells

França¹,

M²,

Pour³

et al. 2022

Preprint

View full text Add to dashboard Cite

Advancements in rational drug design over the past decades have consistently produced new cancer therapies, but such treatments are inevitably countered through an adaptive process that fosters therapy resistance. Malignant cells achieve drug resistance through intrinsic and acquired mechanisms, rooted in genetic and non-genetic determinants. In particular, recent work has highlighted the role of intrinsic cellular heterogeneity in the emergence of transient drug-tolerant persister cells that survive drug treatment, as well as non-genetically driven cell plasticity toward stable resistance. However, these models do not account for the role of dose and treatment duration as extrinsic forces in eliciting cancer cell adaptation. Here, we show that these two components together drive the resistance of ovarian cancer cells to targeted therapy along a trajectory of cellular adaptation, that we denote the 'resistance continuum'. We report that gradual dose exposure and prolonged treatment promote a continuous increase in fitness, and show that this process is mediated by evolving transcriptional, epigenetic and genetic changes that promote multiple cell state transitions. The resistance continuum is underpinned by the assembly of gene expression programs and epigenetically reinforced stress response regulation. Using both in vivo and in vitro models, we found that this process involves widespread reprogramming of cell survival pathways, including interferon response, lineage reprogramming, metabolic rewiring and oxidative stress regulation. Together, the resistance continuum reveals the dynamic nature of cellular adaptation, and carries implications for cancer therapies, as initial exposure to lower doses primes cells over time for increased resistance to higher doses. Beyond cancer, such continuous adaptation exposes a basic aspect of cellular plasticity, which may also be deployed in other biological systems such as development, immune response and host-pathogen interactions.

show abstract